If we forget the comparisons, some of the most interesting information is found in Figure 1 in (1) . This figure highlights that mortality rates increase as hemoglobin levels drop below 3 g/dL. There are few series that describe outcomes from severe anemia in modern ICUs. Here, we see that mortality rates with hemoglobin concentrations below 3 g/dL is over 55% and drop precipitously to somewhere around 28% when hemoglobin concentrations are between 3.1 and 4 g/dL. Anemia in the bloodless group was thought to be the primary cause of death in 36% of all deaths.
Additional information would have been useful to readers. A figure of all patients divided by transfused and not transfused would have also been very useful. Also, it would have been interesting to examine whether such severe anemia also increases other risks: for example, functional outcomes from prolonged ICU stays. These rates, albeit from a single center with extensive experience with extreme anemia, provide some information to provide families of critically ill patients who refuse blood.
Several additional observations are highlighted in these data. First, this center has adopted a restrictive strategy as average lowest hemoglobin concentrations seem to be in the range of 6.4 g/dL even in the transfused group. This would be in keeping with the many randomized trials supporting this practice (3, 4) . Other than restrictive transfusion triggers, one wonders whether they have adopted other practices such as minimizing blood draws and using pediatric tubes for laboratory testing.
In summary, these observations demonstrate that acute severe anemia is lethal. It directly contributes to the death when hemoglobin concentrations fall below 3 g/dL. Furthermore, from the data provided, we would be unable to provide meaningful comparisons of risks of death comparing transfused with nontransfused patients to families when lowest measured hemoglobin concentrations were between 3 and 7 g/dL. W e have learned over the past decade that survivors of critical illness are left with multiple impairments. Resolution of physical deficits, cognitive dysfunction, and return to pre-ICU levels of function are frequently prolonged (1), and complete recovery may never occur. Skeletal muscle weakness acquired during critical illness (ICUacquired weakness [ICUAW]) continues to be a major clinical problem. Importantly, recent studies show that ICUAW is associated with both acute and long-term morbidity and mortality (2) (3) (4) . Although risk factors have been identified, the diagnosis of ICUAW is often delayed, the clinical tools used to assess weakness are imprecise, and the treatments are virtually nonexistent. Furthermore, most existing strategies for preventing or treating ICUAW employ models used to improve muscle strength and endurance in normal healthy individuals and/or the elderly. Currently, one of the most popularized paradigms is early mobilization (EM). This approach gained attention after several studies suggested that mobilizing ICU patients improves outcomes (5) (6) (7) . Numerous reports detail the feasibility of EM, but the barriers remain myriad.
In this issue of Critical Care Medicine, Hodgson et al (8) present results from a pilot study performed to assess whether a higher "dose" of physical therapy (PT) delivered early during critical illness would be feasible and improve mobility milestones in mechanically ventilated patients when compared with a standard care group. This intervention, "early goaldirected mobilization" (EGDM), required subjects to actively participate in PT at the highest level they could achieve at the beginning of the first session, followed by gradual reduction in activity as tolerated. Session durations were targeted for 1 hour daily for 7 days in the EGDM group, and similar to most EM studies, the intervention required a mobility team (an ICU physiotherapist, an allied health assistant, and a nurse). Subjects randomized to standard care received PT at the discretion of a dedicated ICU physiotherapist, consisting initially of passive movements followed by graded increases in active therapy.
Of note, these highly respected investigators who are champions of EM and world leaders in this field executed the protocol in five ICUs across Australia and New Zealand. Results show that EGDM is feasible and safe, and higher levels of activity (measured using the ICU mobility score) and longer durations of exercise were achieved with EGDM. After 7 days, more patients in the EGDM group were able to walk. Interestingly, this was achieved with a median of 20 minutes/d of active therapy in the EGDM group, whereas those in the standard group had a median of 7 minutes/d of active exercise. Although not sufficiently powered to detect differences, duration of mechanical ventilation, ICU and hospital length of stay, and 6-month follow-up data were not different between the two groups.
The authors attempt to address a potentially important issue regarding the optimum exercise dose for critically ill ICU patients. However, the results from the A Very Early Rehabilitation Trial study suggest that in stroke patients, EM is harmful (9) . In addition, Moss et al (10) recently reported that an intensive PT rehabilitation program provided no benefit in longterm outcomes or in ICU or hospital-free days when compared with standard care. In their very thoughtful discussion addressing these negative results, the authors state "it is possible that an intensive PT program truly does not yield better physical function when compared to a standard of care program" (10) . Given these findings, it seems reasonable to wonder whether EM is helpful, or whether this persistent push for widespread implementation of EM for all critically ill patients is simply hype.
Many questions remain regarding the utility of EM as a rehabilitative strategy for critically ill mechanically ventilated patients. Does the time, effort, and additional personnel required for EM benefit our patients? Is EM good for all critically ill patients? Intuitively, we say yes; exercise is good, so it must be good for critically ill patients. Proponents of EM might suggest that the issues are determining what form of PT works, how much PT is needed, and when PT should be initiated. Is it reasonable to continue along this path when we still have significant problems with oversedation and ICUs that have not adopted even the most basic EM protocols because of real or perceived barriers (11) ? How many large trials of exercise in the ICU will be required to unequivocally verify that EM results in clinically important and patient-centered outcomes? If a study emerges with robustly positive results, could the approach be used universally, or would the next study invalidate the positive study, clouding the issue again?
Perhaps it is time for us to step back and reassess. The pathophysiology of ICUAW is complex and cannot be entirely explained by immobilization. Both preclinical and clinical studies provide evidence that multiple contributing pathophysiologic mechanisms are involved in the evolution of ICUAW. Should we continue to ignore these data and limit our exploration merely to delineating the best exercise regimen for our ICU patients? Patients are septic, with respiratory failure, renal failure, and other organ dysfunctions.
Importantly, a significant number of these patients cannot be weaned off mechanical ventilation because of diaphragm weakness (2), a critical component of ICUAW that has received little attention. Certainly, one could argue that liberation from mechanical ventilation eliminates one of the major barriers for implementing a host of interventions that might improve critical illness-induced physical and cognitive dysfunction.
Reducing ICU immobilization is a laudable goal, but we should not be so visionless to think that PT is the only therapeutic option for ICUAW or that exercise is the panacea for eliminating most of the disabilities in ICU survivors. A recent elegant review points out that our patients are both sick and weak (12) . Therefore, we are compelled to consider all of these factors in designing preventive and rehabilitative strategies. There are answers, but we must be broad-minded in our search. New therapies will require careful consideration of the existing science, generation of new data that unfold yet undiscovered mechanisms, and most importantly, ingenuity.
